Results 121 to 130 of about 715,175 (219)

MIND-OUT: Medications in Intensive Care, Delirium and OUTcomes

BJPsych Open
Aims: To investigate how anticholinergic burden of medications changes during hospital stay for Intensive Care Unit (ICU) patients and to review whether anticholinergic burden predicts delirium and mortality.
Hannah Reynolds, Bhamini Patel, Sara Ormerod, Felicity Evison, William Tunnicliffe   +4 more
doaj   +1 more source

Brain Penetrant Calcium Channel Blockers Were Not Associated With Reduced Alcohol Consumption: Converging Results From Two Large Independent Cohort Studies Using Electronic Health Records

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 10, October 2026.
ABSTRACT Purpose Alcohol use disorder (AUD) remains a major public health problem, with few effective treatments. L‐type calcium channel blockers (LTCCBs) have genetic and preclinical support as potential treatments for AUD. Methods We evaluated whether brain penetrant (BP)‐LTCCBs are associated with reduced alcohol consumption in two preregistered ...
Christopher T. Rentsch, Vanessa A. Palzes, Mingjian Shi, Michael R. Setzer, Samantha G. Malone, Andrea H. Kline‐Simon, Emma L. Winterlind, Lorenzo Leggio, Vincent Lo Re III, David A. Fiellin, John Tazare, Mehdi Farokhnia, Stacy Sterling, Henry R. Kranzler, Joshua C. Gray   +14 more
wiley   +1 more source

Anticholinergic medicine burden and older patients [PDF]

, 2009
Anticholinergic medicines are commonly used to treat e.g. incontinence. These medicines have side effects, which may cause and also exacerbate e.g. dryness of the mouth, increased heart rate, and even cognitive impairment.
Kumpula, Eeva-Katri
core  

Anticholinergic Load: Is there a Cognitive Cost in Early Parkinson’s Disease?

Journal of Parkinson’s Disease
We evaluated the effect of anticholinergic burden on 219 participants with incident Parkinson’s disease (PD) and 99 controls at study baseline and 18 months.
Alison J. Yarnall, Rachael A. Lawson, Gordon W. Duncan, David P. Breen, Tien K. Khoo, David Brooks, Roger A. Barker, John-Paul Taylor, David J. Burn   +8 more
doaj   +1 more source

Anticholinergic load: A commonly neglected and preventable risk to cognition during schizophrenia treatment?

Schizophrenia Research: Cognition
Background: Cognitive impairment is a widespread feature of schizophrenia, affecting nearly 80 % of patients. Prior research has linked the anticholinergic burden of psychiatric medications to these cognitive deficits.
Clara Martínez-Cao, Ainoa García-Fernández, Leticia González-Blanco, Pilar A. Sáiz, Julio Bobes, María Paz García-Portilla   +5 more
doaj   +1 more source

Mechanism‐Informed Pharmacotherapy Optimization and Deprescribing: A Redox–Mitochondrial Framework

Pharmacology Research &Perspectives, Volume 14, Issue 5, October 2026.
From cumulative drug burden to mitochondrial stress and functional decline. The graphical abstract summarizes the central concept of the review, illustrating how cumulative pharmacotherapy exposure may contribute to redox–mitochondrial stress and thereby reduce biological and functional resilience.
Boštjan Martinc
wiley   +1 more source

Improving Medication Management in Indonesian Aged Care Homes: Research Priority Setting With Stakeholders

Pharmacology Research &Perspectives, Volume 14, Issue 5, October 2026.
ABSTRACT Indonesia and other Southeast Asian nations are experiencing rapidly aging populations. The Indonesian Government recently announced a national initiative of aged care homes to support older people not able to live independently or receive family care.
Yulisna Mutia Sari, J. Simon Bell, Surya Adhi, Uswa Alhamid, Esthika Dewiasty, Annisa Dhanira, Clara M. Kusharto, Evi Dwi Novriany, Dion Notario, Imran Pambudi, Rocksy Situmeang, Sri Soenarti, M. Rizky Widodo, Grace Wangge   +13 more
wiley   +1 more source

Muscarinic agonists for schizophrenia: Bridging preclinical evidence and clinical enthusiasm

British Journal of Pharmacology, Volume 183, Issue 19, Page 5701-5731, October 2026.
Abstract Antipsychotic drugs targeting dopamine receptors have been used to treat schizophrenia for decades, primarily alleviating positive symptoms such as hallucinations and delusions. However, they provide limited benefit for cognitive and negative symptoms—major contributors to poor outcomes—and are frequently associated with significant side ...
Brian J. Morris, Judith A. Pratt
wiley   +1 more source

Mental Health Disorders in End‐Stage Kidney Disease: A Narrative Review of Clinical Considerations for Integrated Management

Hemodialysis International, Volume 30, Issue 4, Page 679-688, October 2026.
ABSTRACT Introduction End stage kidney disease (ESKD) is associated with a high prevalence of depression and anxiety, arising from both biological factors and the psychosocial burden of chronic dialysis care. Approximately 25%–30% of dialysis patients experience clinically significant depressive symptoms when assessed by structured clinical interview ...
Kunal Malhotra, Jordan Fangue‐Nelon, Garima Singh   +2 more
wiley   +1 more source

Frailty and associated clinical factors among Japanese people with HIV: A multicentre cross‐sectional study using the revised Japanese Cardiovascular Health Study criteria

HIV Medicine, Volume 27, Issue 10, Page 1670-1681, October 2026.
Abstract Objectives Frailty is relevant to HIV care across middle and later life, yet Japanese data remain limited. We evaluated frailty, prefrailty and associated factors in Japanese people with HIV using the revised Japanese Cardiovascular Health Study (J‐CHS) criteria.
Hideta Nakamura, Julian Falutz, Taro Naka, Sho Miyamori, Nanae Ikemiyagi, Kazutaka Yamaniha, Shuhei Ideguchi, Rumi Minami, Masashi Narita, Michinori Shirano, Sei Samukawa, Tomoyuki Endo, Junji Imamura, Mayumi Imahashi, Shinichiro Ueda, Kazuko Yamamoto   +15 more
wiley   +1 more source